Key result
Aspirin is advocated as the preferred agent for venous thromboembolism prevention in noncardiac surgery, reserving potent anticoagulants for highest-risk patients due to adverse event risks.
Why the study?
Does aspirin prevent venous thromboembolism in surgical patients compared to potent anticoagulants?
Does aspirin prevent venous thromboembolism in surgical patients compared to potent anticoagulants?
No takes yet. Share an insight, caveat, or question.
This editorial argues for the use of aspirin over potent anticoagulants for VTE prophylaxis in most noncardiac surgical patients due to a better safety profile.
R. J. Gordon (2017) conducted a letter in Venous thromboembolism. Aspirin vs. Potent anticoagulants was evaluated. Aspirin is advocated as the preferred agent for venous thromboembolism prevention in noncardiac surgery, reserving potent anticoagulants for highest-risk patients due to adverse event risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: